Sevabertinib Approved for HER2-Mutant Nonsquamous NSCLC
Episode Summary
FDA accelerated approval makes sevabertinib available for previously treated advanced nonsquamous NSCLC with qualifying HER2 mutations, emphasizing precise molecular testing and avoiding broad HER2 eligibility.